BRISTOL, England (September 2023) – Siloton Limited, a UK start-up developing personal eye scanners to improve outcomes for patients with macular disease, has been granted its first patent.
GB2601117 protects a key on-chip component that can be used to adapt the system to different imaging distances, with applications in the ophthalmic medical space, as well as in the wider use of hand-held OCT. This type of flexibility is critical for the device’s ability to produce robust medical-grade images despite differences in the distance between the front and back of an individual’s eye.
The patent was granted on 15 August 2023 and published in the Patents and Designs Journal on 13 September 2023.
Dr Alasdair Price, Siloton’s CEO, said:
“We are delighted that our first patent application has now been granted. While patents are an important part of any technology company’s IP strategy, this also demonstrates just how cutting-edge Siloton’s technology is.”
Siloton has a number of other patent applications in progress, both domestically and internationally, in addition to having developed Redfield, its own proprietary photonic chip component library that was designed in-house from scratch.
About Siloton
Siloton is developing an at-home monitoring service for the 25% of over 60’s with age-related macular degeneration (AMD), the leading cause of sight loss in the developed world. By combining a personal optical coherence tomography (OCT) system with cloud-based digital health tools, this will create a paradigm shift in the way patients are cared for, ensuring they receive treatment when they need it, not just when they happen to be able to access an OCT in the hospital.
The effects will be threefold. Patient wellbeing will improve, as they will retain their sight for longer, pressure on overstretched outpatient clinics will be alleviated, and the NHS will save half a billion pounds per annum, even if at-home monitoring is only made available to patients with late-stage AMD.
Siloton closed its first investment round in March 2022, raising c. £485k to fund the design, fabrication and testing of Akepa, as well as its integration into a binocular form factor. Siloton’s next round will soon be closing. Any interested parties still outstanding are invited to get in touch via investors@siloton.com.
To find out more, visit www.siloton.com or follow updates on Siloton’s LinkedIn page.